Outcomes of fetal listed patients awaiting heart transplantation

Jennifer Conway, Maryanne R K Chrisant, Lori J. West, Rebecca K. Ameduri, Juan C. Alejos, Jacqueline M. Lamour, Bibhuti Das, Deborah Gilbert, Margaret Tresler, David C. Naftel, Shelley D. Miyamoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

HTx in neonates is mainstay therapy for those with severe cardiomyopathies and congenital heart disease. Fetal listing for HTx has been proposed as a way to increase the potential window for a donor with outcomes predicted to be similar to the neonatal population. Data from the PHTS, a prospective multicenter study, were used to examine the outcomes of fetuses listed between 1993 and 2009. Four thousand three hundred and sixty-five children were listed for HTx during this period. Fetuses comprised 1% and neonates 19.8% of listed patients. In those patients listed as fetus and transplanted, the median wait time from listing to HTx was 55 days (range 4-255), with a median of 25 days (range 0-233) after birth. By six months post-listing, a higher proportion of fetal listed patients had undergone HTx with a lower waitlist mortality when compared with neonate. There was no significant difference in survival following HTx between the two group (p = 0.4). While the results of this study may be less applicable to current practice due to changes in referrals for fetal listing, they do indicate that fetal listing can be a reasonable option. These results are of particular interest at the present time given the ongoing public discourse on the proposed elimination of fetal listing within UNOS.

Original languageEnglish (US)
Pages (from-to)653-660
Number of pages8
JournalPediatric Transplantation
Volume17
Issue number7
DOIs
StatePublished - Nov 2013

Fingerprint

Heart Transplantation
Fetus
Newborn Infant
Cardiomyopathies
Multicenter Studies
Heart Diseases
Referral and Consultation
Tissue Donors
Parturition
Prospective Studies
Survival
Mortality
Population
Therapeutics

Keywords

  • fetus
  • infant
  • pediatric heart transplant
  • transplant listing

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Conway, J., Chrisant, M. R. K., West, L. J., Ameduri, R. K., Alejos, J. C., Lamour, J. M., ... Miyamoto, S. D. (2013). Outcomes of fetal listed patients awaiting heart transplantation. Pediatric Transplantation, 17(7), 653-660. https://doi.org/10.1111/petr.12130

Outcomes of fetal listed patients awaiting heart transplantation. / Conway, Jennifer; Chrisant, Maryanne R K; West, Lori J.; Ameduri, Rebecca K.; Alejos, Juan C.; Lamour, Jacqueline M.; Das, Bibhuti; Gilbert, Deborah; Tresler, Margaret; Naftel, David C.; Miyamoto, Shelley D.

In: Pediatric Transplantation, Vol. 17, No. 7, 11.2013, p. 653-660.

Research output: Contribution to journalArticle

Conway, J, Chrisant, MRK, West, LJ, Ameduri, RK, Alejos, JC, Lamour, JM, Das, B, Gilbert, D, Tresler, M, Naftel, DC & Miyamoto, SD 2013, 'Outcomes of fetal listed patients awaiting heart transplantation', Pediatric Transplantation, vol. 17, no. 7, pp. 653-660. https://doi.org/10.1111/petr.12130
Conway J, Chrisant MRK, West LJ, Ameduri RK, Alejos JC, Lamour JM et al. Outcomes of fetal listed patients awaiting heart transplantation. Pediatric Transplantation. 2013 Nov;17(7):653-660. https://doi.org/10.1111/petr.12130
Conway, Jennifer ; Chrisant, Maryanne R K ; West, Lori J. ; Ameduri, Rebecca K. ; Alejos, Juan C. ; Lamour, Jacqueline M. ; Das, Bibhuti ; Gilbert, Deborah ; Tresler, Margaret ; Naftel, David C. ; Miyamoto, Shelley D. / Outcomes of fetal listed patients awaiting heart transplantation. In: Pediatric Transplantation. 2013 ; Vol. 17, No. 7. pp. 653-660.
@article{a280c2fa0d194a6c85c7a83323b7cc9d,
title = "Outcomes of fetal listed patients awaiting heart transplantation",
abstract = "HTx in neonates is mainstay therapy for those with severe cardiomyopathies and congenital heart disease. Fetal listing for HTx has been proposed as a way to increase the potential window for a donor with outcomes predicted to be similar to the neonatal population. Data from the PHTS, a prospective multicenter study, were used to examine the outcomes of fetuses listed between 1993 and 2009. Four thousand three hundred and sixty-five children were listed for HTx during this period. Fetuses comprised 1{\%} and neonates 19.8{\%} of listed patients. In those patients listed as fetus and transplanted, the median wait time from listing to HTx was 55 days (range 4-255), with a median of 25 days (range 0-233) after birth. By six months post-listing, a higher proportion of fetal listed patients had undergone HTx with a lower waitlist mortality when compared with neonate. There was no significant difference in survival following HTx between the two group (p = 0.4). While the results of this study may be less applicable to current practice due to changes in referrals for fetal listing, they do indicate that fetal listing can be a reasonable option. These results are of particular interest at the present time given the ongoing public discourse on the proposed elimination of fetal listing within UNOS.",
keywords = "fetus, infant, pediatric heart transplant, transplant listing",
author = "Jennifer Conway and Chrisant, {Maryanne R K} and West, {Lori J.} and Ameduri, {Rebecca K.} and Alejos, {Juan C.} and Lamour, {Jacqueline M.} and Bibhuti Das and Deborah Gilbert and Margaret Tresler and Naftel, {David C.} and Miyamoto, {Shelley D.}",
year = "2013",
month = "11",
doi = "10.1111/petr.12130",
language = "English (US)",
volume = "17",
pages = "653--660",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Outcomes of fetal listed patients awaiting heart transplantation

AU - Conway, Jennifer

AU - Chrisant, Maryanne R K

AU - West, Lori J.

AU - Ameduri, Rebecca K.

AU - Alejos, Juan C.

AU - Lamour, Jacqueline M.

AU - Das, Bibhuti

AU - Gilbert, Deborah

AU - Tresler, Margaret

AU - Naftel, David C.

AU - Miyamoto, Shelley D.

PY - 2013/11

Y1 - 2013/11

N2 - HTx in neonates is mainstay therapy for those with severe cardiomyopathies and congenital heart disease. Fetal listing for HTx has been proposed as a way to increase the potential window for a donor with outcomes predicted to be similar to the neonatal population. Data from the PHTS, a prospective multicenter study, were used to examine the outcomes of fetuses listed between 1993 and 2009. Four thousand three hundred and sixty-five children were listed for HTx during this period. Fetuses comprised 1% and neonates 19.8% of listed patients. In those patients listed as fetus and transplanted, the median wait time from listing to HTx was 55 days (range 4-255), with a median of 25 days (range 0-233) after birth. By six months post-listing, a higher proportion of fetal listed patients had undergone HTx with a lower waitlist mortality when compared with neonate. There was no significant difference in survival following HTx between the two group (p = 0.4). While the results of this study may be less applicable to current practice due to changes in referrals for fetal listing, they do indicate that fetal listing can be a reasonable option. These results are of particular interest at the present time given the ongoing public discourse on the proposed elimination of fetal listing within UNOS.

AB - HTx in neonates is mainstay therapy for those with severe cardiomyopathies and congenital heart disease. Fetal listing for HTx has been proposed as a way to increase the potential window for a donor with outcomes predicted to be similar to the neonatal population. Data from the PHTS, a prospective multicenter study, were used to examine the outcomes of fetuses listed between 1993 and 2009. Four thousand three hundred and sixty-five children were listed for HTx during this period. Fetuses comprised 1% and neonates 19.8% of listed patients. In those patients listed as fetus and transplanted, the median wait time from listing to HTx was 55 days (range 4-255), with a median of 25 days (range 0-233) after birth. By six months post-listing, a higher proportion of fetal listed patients had undergone HTx with a lower waitlist mortality when compared with neonate. There was no significant difference in survival following HTx between the two group (p = 0.4). While the results of this study may be less applicable to current practice due to changes in referrals for fetal listing, they do indicate that fetal listing can be a reasonable option. These results are of particular interest at the present time given the ongoing public discourse on the proposed elimination of fetal listing within UNOS.

KW - fetus

KW - infant

KW - pediatric heart transplant

KW - transplant listing

UR - http://www.scopus.com/inward/record.url?scp=84885430979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885430979&partnerID=8YFLogxK

U2 - 10.1111/petr.12130

DO - 10.1111/petr.12130

M3 - Article

VL - 17

SP - 653

EP - 660

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 7

ER -